ARS Pharmaceuticals, Inc. — Director's Dealing 2020

Dec 8, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2020-12-03

Reporting Person: Shawver Laura (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-03	Stock Option (right to buy)	$21.00	A	562631	Acquired	2030-12-02	Common Stock (562631)	Direct

Footnotes

F1: The shares subject to the option vest in equal monthly installments over the 48 months following December 3, 2020.